Treatment-related adverse events of antibody drug-conjugates in clinical trials

Abstract Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 tri...

Descripción completa

Detalles Bibliográficos

Autores principales:	Harold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, Anna Minchom, Adam Sharp, Alec Paschalis, Georgina Silva-Fortes, Bindu Raobaikady, Udai Banerji
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2025-07-01
Colección:	Journal of Hematology & Oncology
Materias:	ADCs AEs Clinical trials
Acceso en línea:	https://doi.org/10.1186/s13045-025-01720-3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!